CAMBRIDGE, Mass.--(BUSINESS WIRE)--A recent study of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) has enabled a new understanding of the rare and fatal disease. The study explored the diagnosis, progression and mortality of the disease, and resulted in new insight into measures of disease progression as well as potential predictors of survival. Currently there is no available disease modifying pharmacologic therapy for ATTR-CM, and these significant strides in expanding the limited understanding of ATTR-CM will guide development of novel therapeutics for the disease.
